XML 70 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Asset and Liability The following table summarizes the values of contract assets, capitalized commissions and contract liabilities as of December 31, 2020 and December 31, 2019 (in thousands):
December 31, 2020December 31, 2019
Current pharma contract assets(1)
$1,643 $1,000 
Long-term pharma contract assets(2)
290 153 
Total pharma contract assets$1,933 $1,153 
Current pharma capitalized commissions(1)
$185 $133 
Long-term pharma capitalized commissions(2)
970 798 
Total pharma capitalized commissions$1,155 $931 
Current pharma contract liabilities$4,029 $1,610 
Long-term pharma contract liabilities(3)
712 1,171 
Total pharma contract liabilities$4,741 $2,781 

(1) Current pharma contract assets and current pharma capitalized commissions are recorded within “other current assets” on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and long-term pharma capitalized commissions are recorded within “other assets” on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are recorded within “other long-term liabilities” on the Consolidated Balance Sheets.
Disaggregation of Revenue The following table details the disaggregation of revenue for both the Clinical Services and Pharma Services Segments (in thousands):
December 31, 2020December 31, 2019December 31, 2018
Clinical Services:
    Client direct billing$240,535 $212,703 $164,888 
    Commercial insurance76,550 83,107 40,360 
    Medicare and other government64,776 64,745 35,566 
    Self-Pay476 606 1,059 
Total Clinical Services382,337 361,161 241,873 
Pharma Services:62,111 47,669 34,868 
Total Revenue$444,448 $408,830 $276,741